LONGJUMEAU, France, June 8, 2021 /PRNewswire/ — The French biotech TargEDys specialised in breakthrough microbiome-based options declares the publication of its research performed in 230 obese adults supplemented for 12 weeks, confirming the efficacy of the precision probiotic Hafnia alvei HA4597® to enhance weight reduction, hip circumference discount and metabolic parameters due to the motion of the probiotic and its postbiotic ClpB on feeling of fullness.
Mechanistic and preclinical research confirmed Hafnia alvei is ready to produce Caseinolytic peptidase B, a protein mimicking the hormone of satiety alpha-MSH, and to cut back meals consumption in murine fashions of weight problems. These new outcomes verify the efficacy of this PreciBiomic™ pressure in supporting feeling of fullness and weight reduction in obese topics, in addition to lowering hip circumference and glycemia.
With a median of three,6% weight reduction in 12 weeks within the probiotic group, Hafnia alvei is dramatically more practical than every other probiotic studied in weight administration, and this degree of affect fills the hole between the sectors of meals dietary supplements and medicines. It additionally drives innovation within the probiotics subject, shifting the strategy to precision probiotics, with enhanced efficacy due to the exact understanding of the molecular mechanism of motion.
Hafnia alvei may be discovered within the merchandise EnteroSatys® and Satylia® in France, Portugal, Italy and Slovenia, and TargEDys is on the lookout for distribution companions to make this breakthrough answer for the prevention of weight problems obtainable to customers worldwide.
Grégory Lambert, CEO of TargEDys, declares:
“This might be a game-changer within the sector of weight administration, with lastly an answer that meets customers expectations by way of security and naturality, whereas additionally bringing an actual, demonstrated efficacy based mostly on molecular mimicry and the biochemical regulation of urge for food.”
TargEDys® is a commercial-stage French biotech specialised within the growth of nutraceutical options for the management of urge for food by way of microbiome interventions. The corporate is the fruit of 15 years of analysis on the microbiota performed inside tutorial laboratories. The corporate developed and began the commercialization of its first product based mostly on the PreciBiomic pressure Hafnia alvei HA4597™ and develops a product portfolio specializing in obese, undernutrition and psychological well being, all based mostly on the idea of precibiomic strains backed by a molecular mechanism of motion and in vivo research.
Extra info at www.targedys.com
Contact: Arnaud Faure & Nina Vinot; [email protected]